A dominant negative TAK1 inhibits cellular fibrotic responses induced by TGF-β

Biochemical and Biophysical Research Communications

Volumn 307, Issue 2, 2003, Pages 332-337

  Ono, Koichiro ^a   Ohtomo, Toshihiko ^a   Ninomiya Tsuji, Jun ^b   Tsuchiya, Masayuki ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Dominant negative inhibitor; Fibrotic marker proteins; TGF activated kinase 1; Transforming growth factor

Indexed keywords

BINDING PROTEIN; BIOCHEMICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PHOSPHOTRANSFERASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1 BINDING PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1 DOMINANT NEGATIVE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ACTIVITY; CELL STIMULATION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 0038351964     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01207-5     Document Type: Article

References (24)

1. Poli G. Pathogenesis of liver fibrosis. Mol. Aspects Med. 21:2000;49-98.
2. Coker R.K., Laurent G.J. Pulmonary fibrosis: cytokines in the balance. Eur. Respir. J. 11:1998;1218-1221.
3. Border W.A., Noble N.A. Transforming growth factor β in tissue fibrosis. N. Engl. J. Med. 331:1994;1286-1292.
4. Basile D.P. The transforming growth factor β system in kidney disease and repair: recent progress and future directions. Curr. Opin. Nephrol. Hypertens. 8:1999;21-30.
5. Border W.A., Noble N.A. Transforming growth factor β in tissue fibrosis. N. Engl. J. Med. 331:1994;1286-1292.
6. Vangelista A., Frasca G.M., Severi B., Bonomini V. The role of myofibroblasts in renal interstitial fibrosis and their relationship with fibronectin and type IV collagen. Contrib. Nephrol. 70:1989;135-141.
7. Downer G., Phan S.H., Wiggins R.C. Analysis of renal fibrosis in a rabbit model of crescentic nephritis. J. Clin. Invest. 82:1988;998-1006.
8. Murawaki Y., Koda M., Okamoto K., Mimura K., Kawasaki H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. Gastroenterol. Hepatol. 16:2001;777-781.
9. Yamaguchi K., Shirakabe K., Shibuya H., Irie K., Oishi I., Ueno N., Taniguchi T., Nishida E., Matsumoto K. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science. 270:1995;2008-2011.
10. Shibuya H., Yamaguchi K., Shirakabe K., Tonegawa A., Gotoh Y., Ueno N., Irie K., Nishida E., Matsumoto K. TAB1: an activator of the TAK1 MAPKKK in TGF-β signal transduction. Science. 272:1996;1179-1182.
11. Shibuya H., Iwata H., Masuyama N., Gotoh Y., Yamaguchi K., Irie K., Matsumoto K., Ueno E., Nishida N. Role of TAK1 and TAB1 in BMP signaling in early Xenopus development. EMBO J. 17:1998;1019-1028.
12. Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z., Matsumoto K. The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature. 398:1999;252-256.
13. Yamaguchi K., Nagai S.I., Ninomiya-Tsuji J., Nishita M., Tamai K., Irie K., Ueno N., Nishida E., Shibuya H., Matsumoto K. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J. 18:1999;179-187.
14. Zhou G., Lee S.C., Yao Z., Tan T.H. Hematopoietic progenitor kinase 1 is a component of transforming growth factor β-induced c-Jun N-terminal kinase signaling cascade. J. Biol. Chem. 274:1999;13133-13138.
15. Hanafusa H., Ninomiya-Tsuji J., Masuyama N., Nishita M., Fujisawa J., Shibuya H., Matsumoto K., Nishida E. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression. J. Biol. Chem. 274:1999;27161-27167.
16. Dempsey C.E., Sakurai H., Sugita T., Guesdon F. Alternative splicing and gene structure of the transforming growth factor β-activated kinase 1. Biochim. Biophys. Acta. 1517:2000;46-52.
17. Ohtomo T., Sugamata Y., Ozaki Y., Ono K., Yoshimura Y., Kawai S., Koishihara Y., Ozaki S., Kosaka M., Hirano T., Tsuchiya M. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 258:1999;583-591.
18. Ignotz R.A., Massague J. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem. 261:1986;4337-4345.
19. Laiho M., Saksela O., Keski-Oja J. Transforming growth factor-β induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J. Biol. Chem. 262:1987;17467-17474.
20. Kasuga H., Ito Y., Sakamoto S., Kawachi H., Shimizu F., Yuzawa Y., Matsuo S. Effects of anti-TGF-β type II receptor antibody on experimental glomerulonephritis. Kidney Int. 60:2001;1745-1755.
21. Isaka Y., Brees D.K., Ikegaya K., Kaneda Y., Imai E., Noble N.A., Border W.A. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat. Med. 2:1996;418-423.
22. Ono K., Ohtomo T., Sato S., Sugamata Y., Suzuki M., Hisamoto N., Ninomiya-Tsuji J., Tsuchiya M., Matsumoto K. An evolutionarily conserved motif in the TAB1 C-terminal region is necessary for interaction with and activation of TAK1 MAPKKK. J. Biol. Chem. 276:2001;24396-24400.
23. Liuzzi M., Deziel R., Moss N., Beaulieu P., Bonneau A.M., Bousquet C., Chafouleas J.G., Garneau M., Jaramillo J., Krogsrud R.L., Lagace L., McCollum R.S., Nawoot S., Guindon Y. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature. 372:1994;695-698.
24. Ninomiya-Tsuji J., Kajino T., Ono K., Ohtomo T., Matsumoto M., Shiina M., Mihara M., Tsuchiya M., Matsumoto K. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J. Biol. Chem. 278:2003;18485-18490.